^
Association details:
| Biomarker: | JAK2 mutation + CRLF2 rearrangement |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Excerpt:
Three JAK2m/CRLF2R ALL xenografts (I, II, III), including the sample harboring a P2RY8-CRLF2 fusion, exhibited significantly decreased leukemia burden with ruxolitinib treatment compared with vehicle...
DOI:
https://dx.doi.org/10.1182%2Fblood-2012-03-415448
